Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026
Key Highlights
- ➤FDA-cleared next-generation BVA platform targets hospital and outpatient clinical adoption
- ➤BVA platform operates 3x faster than predecessor BVA-100
- ➤BVA platform requires 50% less patient blood
- ➤BVA platform delivers >95% measurement accuracy
- ➤Independent investigators will present two new advanced heart failure studies at HFSA
Expert Statements
John L. Jefferies, Chief Medical Officer of Daxor
“Precise volume management is fundamental to improving outcomes in heart failure, yet clinicians have historically relied on indirect surrogates and subjective estimation.”
John L. Jefferies, Chief Medical Officer of Daxor
“Our next-generation BVA system eliminates guesswork by accelerating clinical workflow 3x while utilizing half the sample volume.”
John L. Jefferies, Chief Medical Officer of Daxor
“Removing these traditional operational barriers empowers heart failure teams to rapidly optimize therapy, reduce hospital length of stay, and prevent costly readmissions.”
Jonathan Feldschuh, Chief Scientific Officer of Daxor
“By directly measuring red blood cell volume and plasma volume, BVA reveals critical underlying derangements—such as hidden anemia or true dilutional overload—that traditional surrogates simply miss.”
Jonathan Feldschuh, Chief Scientific Officer of Daxor
“The independent research featured at HFSA demonstrates how unmasking these distinct volume phenotypes allows clinicians to deliver targeted, individualized interventions for even the most complex advanced heart failure patients.”
FDA 510(k)-cleared next-generation diagnostic platform delivers 3x faster results with 50% less blood, setting a new standard for data-driven heart failure management.
Key Highlights: * Commercial Acceleration: Daxor to feature its FDA-cleared, next-generation Blood Volume Analyzer (BVA(™)) designed for rapid clinical adoption across hospital systems and outpatient clinics * Clinical Evidence: Independent clinical investigators to present two ePosters highlighting how BVA addresses volume derangements in complex heart failure, LVAD, and total artificial heart patients * On-Site Demonstrations: Daxor participating in HFSA’s dedicated Device Day and exhibiting at Booth #803 in Phoenix, AZ (October 9–12, 2026) OAK RIDGE, Tenn., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announced today it will exhibit at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Phoenix, Arizona, from October 9–12, 2026. Daxor will showcase its FDA 510(k)-cleared, next-generation Blood Volume Analyzer (BVA)—signaling a new era of data-driven fluid management across a multi-billion-dollar addressable market.
Get started
Create a free account to read the full story.